All In Biotech

Drug Trial Radar · NCT07810010

Phase 2b Study of a Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Protein Vaccine Candidate in Adults 60 Years of Age and Older

A Phase 2b, Randomized, Placebo-controlled, Observer-blind Study in Adults 60 Years of Age and Older to Evaluate the Efficacy, Safety, and Immunogenicity of a Bivalent Protein Vaccine Candidate Against Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (HMPV)

Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 8,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

8,000

Planned (sponsor's estimate)

Start

Sep 9, 2026

Primary completion

Jul 3, 2028

Study completion Jul 5, 2028

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Sep 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Study VCA25397 is a Phase 2b, observer-blind, randomized, placebo-controlled, parallel, case-driven proof of concept study that will enroll approximately 8000 adults aged 60 years and older to assess the clinical efficacy, safety, and immunogenicity of a single IM (intramuscular) injection of the bivalent RSV+HMPV protein vaccine candidate. The study will include a Safety Lead-in Cohort that will be enrolled first and will comprise 200 participants aged 60 years and older randomized in a 1:1 ratio to receive either RSV+HMPV protein vaccine or placebo (100 participants per arm). The enrollment of the Main Cohort will start after the completion of the ESDR (Early Safety Data Review), pending a positive outcome. For the Main Cohort, 7800 participants (3900 participants per arm) will be randomized in a 1:1 ratio to receive either RSV+HMPV protein vaccine or placebo.

Conditions

  • Respiratory Syncytial Virus
  • Human Metapneumovirus
  • Healthy Volunteers

Interventions

  • Bivalent RSV+HMPV protein vaccineBiological

    IM injection

  • PlaceboBiological

    IM injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of the first episode of RSV-LRTD (Lower Respiratory Tract Disease)Time frame: From 14 days to 12 months after vaccination
  2. Occurrence of the first episode of HMPV-LRTDTime frame: From 14 days to 12 months after vaccination

Locations

21 sites in 2 countries. Site status is shown where the registry gives one.

  • Investigational Site Number : 0360008

    Bruse, Australian Capital Territory, Australia · Recruiting

  • Investigational Site Number : 0360006

    Blacktown, New South Wales, Australia · Recruiting

  • Investigational Site Number : 0360007

    Maroubra, New South Wales, Australia · Recruiting

  • Investigational Site Number : 0360002

    Albion, Queensland, Australia · Recruiting

  • Investigational Site Number : 0360003

    Sippy Downs, Queensland, Australia · Recruiting

  • Investigational Site Number : 0360009

    Melbourne, Victoria, Australia · Recruiting

  • Investigational Site Number : 8260003

    Bradford, United Kingdom · Recruiting

  • Investigational Site Number : 8260004

    London, United Kingdom · Recruiting

  • Investigational Site Number : 8260008

    Stockton-on-Tees, United Kingdom · Recruiting

  • Investigational Site Number : 8260012

    Cardiff, Cardiff [Caerdydd Gb-crd], United Kingdom · Recruiting

  • Investigational Site Number : 8261010

    Bournemouth, Dorset, United Kingdom · Recruiting

  • Investigational Site Number : 8263010

    Dorchester, Dorset, United Kingdom · Recruiting

  • Investigational Site Number : 8260013

    London, England, United Kingdom · Recruiting

  • Investigational Site Number : 8260011

    London, England, United Kingdom · Recruiting

  • Investigational Site Number : 8262010

    Portsmouth, Hampshire, United Kingdom · Recruiting

  • Investigational Site Number : 8260002

    Blackpool, Lancashire, United Kingdom · Recruiting

  • Investigational Site Number : 8260007

    London, London, City of, United Kingdom · Recruiting

  • Investigational Site Number : 8260001

    Corby, Northamptonshire, United Kingdom · Recruiting

  • Investigational Site Number : 8260005

    Witney, Oxfordshire, United Kingdom · Recruiting

  • Investigational Site Number : 8260009

    Bromborough, Wirral, United Kingdom · Recruiting

  • Investigational Site Number : 8260006

    West Kirby, Wirral, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.